Targeted therapies provide substantial benefits to cancer patients by shrinking and
controlling tumors. However, the long-term efficacy of targeted therapy is limited by the …

When metastatic cancers are challenged with targeted agents, almost invariably a subset of
cells insensitive to the drug emerges. As a result, in most instances, targeted therapies are …

Resistance of neoplastic cells to therapy is considered a key challenge in the treatment of
cancer. Emergence of resistance is commonly attributed to the gradual mutational evolution …

Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …

Drug resistance is a serious impediment to the treatment of cancer. However, the
mechanisms involved remain poorly understood. While it is widely held that the …

Mutational processes and nongenetic phenotypic state transitions represent distinct
paradigms for understanding acquired resistance to targeted therapies. While ample …

Colorectal cancer is the second leading cause of cancer-related deaths in the world. Despite
many therapeutic opportunities, prognosis remains dismal for patients with metastatic …

In the last two decades major improvements have been reached in the early diagnosis of
colorectal cancer (CRC) and, besides chemotherapy, an ampler choice of therapeutic …

Improvements in screening and preventive measures have led to an increased detection of
early stage colorectal cancers (CRC) where patients undergo treatment with a curative …